Payment overview · 2025
General Payments
$267.11
13 reported records · 9 companies
Healthcare provider profile · identity verified
Salman N Malik, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · LIBERTY, MO · NPI 1497794499
Verified facts
What the public records show
CMS Open Payments records show Salman N Malik, M.D. received $267.11 in general payments during 2025 across 13 reported records.
Biogen, Inc. accounted for 28.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Nurtec Odt.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nurtec Odt by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Biogen, Inc. | Unresolved — no canonical attribution shown | $76.90 | 28.8% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $49.68 | 18.6% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $26.41 | 9.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $23.43 | 8.8% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.84 | 7.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.24 | 7.6% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.24 | 6.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.19 | 6.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.18 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $267.11 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $76.90 | 4 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $49.68 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $26.41 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 863 | 164 |
| Donepezil Hcl | Donepezil Hcl | 515 | 112 |
| Gabapentin | Gabapentin | 485 | 110 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 317 | 66 |
| Topiramate | Topiramate | 290 | 62 |
| Levetiracetam | Levetiracetam | 277 | 57 |
| Primidone | Primidone | 192 | 35 |
| Baclofen | Baclofen | 174 | 35 |
| Lamotrigine | Lamotrigine | 142 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 122 | 22 |
| Clonazepam | Clonazepam | 117 | 19 |
| Pregabalin | Pregabalin | 100 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 16 |
| Lacosamide | Lacosamide | 89 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 86 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 30 |
| Divalproex Sodium | Divalproex Sodium | 63 | 13 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 60 | 15 |
| Tramadol Hcl | Tramadol Hcl | 60 | suppressed |
| Zonisamide | Zonisamide | 60 | 14 |
| Memantine Hcl Er | Memantine Hcl | 59 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 12 |
| Buspirone Hcl | Buspirone Hcl | 55 | 15 |
| Carbamazepine | Carbamazepine | 52 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 51 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 11 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 47 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 13 |
| Amantadine | Amantadine Hcl | 45 | 13 |
| Sertraline Hcl | Sertraline Hcl | 44 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 41 | 13 |
| Alprazolam | Alprazolam | 37 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 37 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 35 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Galantamine Er | Galantamine Hbr | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | 13 |
| Prednisone | Prednisone | 28 | 11 |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Briviact | Brivaracetam | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 15 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 15 | suppressed |
| Diflunisal | Diflunisal | 14 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 14 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Ergotamine-Caffeine | Ergotamine Tartrate/Caffeine | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Risperidone Odt | Risperidone | 13 | suppressed |
| Tetrabenazine | Tetrabenazine | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Austedo | Deutetrabenazine | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $267.11 · 13 records | Biogen, Inc. | AUSTEDO XR, INGREZZA, KESIMPTA, NURTEC ODT, PONVORY, Rystiggo, TYSABRI, Tascenso ODT, VYEPTI, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Neurocrine BioSciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error